GPR103拮抗剂表现出体内的厌食活性:模仿QRFP26的C端Arg-Phe基序的吡咯并[2,3- c ]吡啶的设计与开发。
摘要:
据报道,GPR103是一种G蛋白偶联受体,通过内源性神经肽配体QRFP26和QRFP43的激活而具有致癌作用。认识到QRFP26和QRFP43的中央给药可增加大鼠的高脂肪食物摄入量,因此我们决定研究GPR103的拮抗剂是否可以在控制喂养行为中发挥作用。在这里,我们介绍了作为GPR103小分子拮抗剂的吡咯并[2,3- c ]吡啶新系列的开发,这些拮抗剂具有GPR103亲和力,药物代谢和药代动力学以及适合药物开发的安全性参数。在测量食物摄入量的临床前肥胖模型中,吡咯并[2,3- c证明了吡啶吡啶GPR103拮抗剂。此外,使用NMR确定了内源性激动剂QRFP26 (20–26)的C端七肽的动态3D溶液结构。将合成的吡咯并[2,3- c ]吡啶拮抗剂与该实验结构进行了比较,该实验结构显示了可能的药效团特征重叠,为进一步设计GPR103拮抗剂提供了支持。
[EN] SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS CYCLIQUES SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION
申请人:CALITOR SCIENCES LLC
公开号:WO2014089324A1
公开(公告)日:2014-06-12
The present invention provides novel substituted alkynyl compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.
Synthesis and fluorescent properties of boroisoquinolines, a new family of fluorophores
作者:Dénes Sóvári、Attila Kormos、Orsolya Demeter、András Dancsó、György Miklós Keserű、Mátyás Milen、Péter Ábrányi-Balogh
DOI:10.1039/c8ra08241c
日期:——
First representatives of a new family of isoquinolines, so called boroisoquinolines, were synthesized and characterized.
首次合成并表征了一种新的异喹啉家族代表,被称为硼异喹啉。
Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine
申请人:Danysz Wojciech
公开号:US20080039458A1
公开(公告)日:2008-02-14
Substituted pyrazolopyrimidine derivatives of formula (I)
wherein
Y
1
, Y
2
, Y
3
, Y
4
represent N or C—, whereby at least two of the groups Y
1
to Y
4
represent a carbon atom, R
1
represents chloro or bromo,
R
2
to R
7
represent e.g. hydrogen, methyl or ethyl; and
R
10
and R
11
independently represent e.g. hydrogen or C
1
-C
6
alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators
申请人:MERZ PHARMA GmbH & Co. KGaA
公开号:US07985753B2
公开(公告)日:2011-07-26
Substituted pyrazolopyrimidine derivatives of formula (I)
wherein
Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo,
R2 to R7 represent e.g. hydrogen, methyl or ethyl; and
R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl,
are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
Substituted pyrazolopyrimidine derivatives of formula (I)
wherein
Y
1
, Y
2
, Y
3
, Y
4
represent N or C—, whereby at least two of the groups Y
1
to Y
4
represent a carbon atom, R
1
represents chloro or bromo,
R
2
to R7 represent e.g. hydrogen, methyl or ethyl; and
R
10
and R
11
independently represent e.g. hydrogen or C
1
-C
6
alkyl,
are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.